Skip to main content

Table 2 IRR of time to first AE. Poisson regression model crude and adjusted

From: Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register

VariablesCrude IRR (CI95%)pAdjusted IRR (CI95%)p
Age (ref. adult)*
 Young0.76 (0.54–1.09)0.1401.00 (0.66–1.53)0.985
 Elderly1.61 (1.36–1.91)< 0.0011.42 (1.13–1.77)0.002
 Very elderly2.01 (1.45–2.79)< 0.0011.89 (1.27–2.81)0.002
Female gender1.33 (1.20–1.49)< 0.0011.43 (1.23–1.66)< 0.001
Diagnosis (ref. RA)
 AS0.80 (0.70–0.91)0.0011.10 (0.91–1.33)0.336
 PsA0.96 (0.84–1.09)0.5121.12 (0.94–1.33)0.208
Comorbidities
 Charlson Index1.15 (1.09–1.22)< 0.0011.14 (1.07–1.22)< 0.001
 Smoking (ref. No)    
 Smoker/past smoker1.25 (1.11–1.41)< 0.0011.31 (1.12–1.52)0.001
Treatments
 Corticosteroids (ref. No)1.31 (1.17–1.46)< 0.0011.1 (0.96–1.26)0.192
 Initial mean dose corticosteroids1.00 (0.99–1.01)0.8420.99 (0.97–1.00)0.100
 MTX (ref. No)1.41 (1.26–1.58)< 0.0011.40 (1.22–1.61)< 0.001
 Other DMARDs (ref. No)1.17 (1.05–1.31)0.0061.29 (1.12–1.50)0.001
Time of disease duration&1.01 (1.00–1.01)0.0541.14 (1.07–1.22)< 0.001
  1. AS ankylosing spondylitis, DMARDs disease-modifying antirheumatic drugs, IRR incidence rate ratio, MTX methotrexate, PsA psoriatic arthritis, RA rheumatoid arthritis, TNFi tumor necrosis factor inhibitor
  2. *Age at the beginning of biological treatment